SCHEMBL4585439

SCHEMBL4585439

C[C@H](O[Si](C)(C)C(C)(C)C)[C@@H](CCc1cccc2oc(-c3ccc(Cl)c(Cl)c3)nc12)n1cnc(C(N)=O)c1

nearest known ligand 0.66

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
ADA P00813 11/20 0.66
MAPT P10636 2/20 0.33
PKM P14618 1/20 0.31
UTRN P46939 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4584138 0.92 ADA (0.67) ADAMAPTPKM
SCHEMBL4585448 0.92 ADA (0.78) ADA
SCHEMBL4582650 0.90 ADA (0.67) ADAUTRN
SCHEMBL4583746 0.90 ADA (0.67) ADA
SCHEMBL4584354 0.89 ADA (0.65) ADAMAPT
SCHEMBL4584370 0.88 ADA (0.84) ADAMAPTPKM
SCHEMBL4584798 0.88 ADA (0.65) ADAMAPT
SCHEMBL4584009 0.87 ADA (0.64) ADAMAPT
SCHEMBL4585444 0.82 ADA (0.49) ADAMAPT
SCHEMBL4584972 0.81 ADA (0.78) ADA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7317107-B2 Imidazole 4-carboxamide compounds with adenosine deaminase inhibiting activity ASTELLAS PHARMA INC. (JP) 2008-01-08 US disclosed
US-20050159462-A1 Imidazole 4-carboxamide compounds with adenosine deaminase inhibiting activity ASTELLAS PHARMA INC. (JP) 2005-07-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050159462-A1 Imidazole 4-carboxamide compounds with adenosine deaminase inhibiting activity ADA, AMPD2, AMPD1 ADA 1/4885MAPT 4738/4885PKM 3152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.